{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:04Z","timestamp":1787020864406,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01696-9","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:26:01Z","timestamp":1739424361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia"],"prefix":"10.1186","volume":"17","author":[{"given":"Constance","family":"Delaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germain","family":"Busto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Bennys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mui\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Villatoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Fern\u00e1ndez-Cadenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pradeilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaima El","family":"Bounasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"2","key":"1696_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3324\/haematol.2019.232124","volume":"105","author":"C Camaschella","year":"2020","unstructured":"Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260\u201372.","journal-title":"Haematologica"},{"issue":"11","key":"1696_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nrn1537","volume":"5","author":"L Zecca","year":"2004","unstructured":"Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863\u201373.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1696_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/antiox10010061","volume":"10","author":"PJ Urrutia","year":"2021","unstructured":"Urrutia PJ, B\u00f3rquez DA, N\u00fa\u00f1ez MT. Inflaming the Brain with Iron. Antioxidants (Basel). 2021;10(1):61.","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"1696_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/jmri.21731","volume":"29","author":"MD Meadowcroft","year":"2009","unstructured":"Meadowcroft MD, Connor JR, Smith MB, Yang QX. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer\u2019s disease and APP\/PS1 transgenic mice. J Magn Reson Imaging. 2009;29(5):997\u20131007.","journal-title":"J Magn Reson Imaging"},{"key":"1696_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117433","volume":"224","author":"PM Cogswell","year":"2021","unstructured":"Cogswell PM, Wiste HJ, Senjem ML, Gunter JL, Weigand SD, Schwarz CG, et al. Associations of quantitative susceptibility mapping with Alzheimer\u2019s disease clinical and imaging markers. Neuroimage. 2021;224: 117433.","journal-title":"Neuroimage"},{"issue":"3","key":"1696_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1021\/cn5003557","volume":"6","author":"DJ Hare","year":"2015","unstructured":"Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, et al. Decreased plasma iron in Alzheimer\u2019s disease is due to transferrin desaturation. ACS Chem Neurosci. 2015;6(3):398\u2013402.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1696_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13195-020-00634-1","volume":"12","author":"A Ashraf","year":"2020","unstructured":"Ashraf A, Ashton NJ, Chatterjee P, Goozee K, Shen K, Fripp J, et al. Plasma transferrin and hemopexin are associated with altered A\u03b2 uptake and cognitive decline in Alzheimer\u2019s disease pathology. Alzheimers Res Ther. 2020;12(1):72.","journal-title":"Alzheimers Res Ther"},{"key":"1696_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2019.06.008","volume":"403","author":"OJ Kweon","year":"2019","unstructured":"Kweon OJ, Youn YC, Lim YK, Lee MK, Kim HR. Clinical utility of serum hepcidin and iron profile measurements in Alzheimer\u2019s disease. J Neurol Sci. 2019;403:85\u201391.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1696_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14336\/AD.2016.0811","volume":"8","author":"Z Sternberg","year":"2017","unstructured":"Sternberg Z, Hu Z, Sternberg D, Waseh S, Quinn JF, Wild K, et al. Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer\u2019s Disease. Aging Dis. 2017;8(2):215\u201327.","journal-title":"Aging Dis"},{"issue":"2","key":"1696_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00702-022-02474-9","volume":"129","author":"C Delaby","year":"2022","unstructured":"Delaby C, Alcolea D, Hirtz C, Vialaret J, Kindermans J, Morichon L, et al. Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. J Neural Transm (Vienna). 2022;129(2):231\u20137.","journal-title":"J Neural Transm (Vienna)"},{"issue":"10004","key":"1696_CR11","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","volume":"386","author":"JT O\u2019Brien","year":"2015","unstructured":"O\u2019Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698\u2013706.","journal-title":"Lancet"},{"issue":"7","key":"1696_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1474-4422(09)70127-9","volume":"8","author":"H Chabriat","year":"2009","unstructured":"Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8(7):643\u201353.","journal-title":"Lancet Neurol"},{"issue":"11","key":"1696_CR13","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.3390\/ijms20112812","volume":"20","author":"V Cipollini","year":"2019","unstructured":"Cipollini V, Troili F, Giubilei F. Emerging Biomarkers in Vascular Cognitive Impairment and Dementia: From Pathophysiological Pathways to Clinical Application. Int J Mol Sci. 2019;20(11):2812.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1696_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3233\/JAD-151037","volume":"51","author":"Y Moon","year":"2016","unstructured":"Moon Y, Han SH, Moon WJ. Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer\u2019s Dementia Using Quantitative Susceptibility Mapping Imaging. J Alzheimers Dis. 2016;51(3):737\u201345.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1696_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-190654","volume":"73","author":"S Emrani","year":"2020","unstructured":"Emrani S, Lamar M, Price CC, Wasserman V, Matusz E, Au R, et al. Alzheimer\u2019s\/Vascular Spectrum Dementia: Classification in Addition to Diagnosis. J Alzheimers Dis. 2020;73(1):63\u201371.","journal-title":"J Alzheimers Dis"},{"key":"1696_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103485","volume":"39","author":"X Jia","year":"2023","unstructured":"Jia X, Li Y, Ying Y, Jia X, Tang W, Bian Y, et al. Effect of corticosubcortical iron deposition on dysfunction in CADASIL is mediated by white matter microstructural damage. Neuroimage Clin. 2023;39: 103485.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"1696_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/acn3.678","volume":"6","author":"G Gravesteijn","year":"2019","unstructured":"Gravesteijn G, Rutten JW, Verberk IMW, B\u00f6hringer S, Liem MK, van der Grond J, et al. Serum Neurofilament light correlates with CADASIL disease severity and survival. Ann Clin Transl Neurol. 2019;6(1):46\u201356.","journal-title":"Ann Clin Transl Neurol"},{"key":"1696_CR18","doi-asserted-by":"publisher","first-page":"6612871","DOI":"10.1155\/2020\/6612871","volume":"2020","author":"W Ma","year":"2020","unstructured":"Ma W, Zhang J, Xu J, Feng D, Wang X, Zhang F. Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia. Dis Markers. 2020;2020:6612871.","journal-title":"Dis Markers"},{"issue":"2","key":"1696_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024;4(2):247\u201360.","journal-title":"Nat Aging"},{"issue":"3","key":"1696_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association. 2011;7(3):270\u20139.","journal-title":"Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association"},{"issue":"3","key":"1696_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1696_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-023-01188-8","volume":"15","author":"C Hirtz","year":"2023","unstructured":"Hirtz C, Busto GU, Bennys K, Kindermans J, Navucet S, Tiers L, et al. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer\u2019s disease diagnosis in a memory clinic cohort. Alzheimers Res Ther. 2023;15(1):34.","journal-title":"Alzheimers Res Ther"},{"key":"1696_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Clarim\u00f3n J, Carmona-Iragui M, Ill\u00e1n-Gala I, Morenas-Rodr\u00edguez E, Barroeta I, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y). 2019;5:597\u2013609.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"1696_CR24","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1038\/s41598-019-44173-8","volume":"9","author":"E Morenas-Rodr\u00edguez","year":"2019","unstructured":"Morenas-Rodr\u00edguez E, Alcolea D, Su\u00e1rez-Calvet M, Mu\u00f1oz-Llahuna L, Vilaplana E, Sala I, et al. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer\u2019s disease. Sci Rep. 2019;9(1):7803.","journal-title":"Sci Rep"},{"issue":"2","key":"1696_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.0000000000004088","volume":"89","author":"D Alcolea","year":"2017","unstructured":"Alcolea D, Vilaplana E, Su\u00e1rez-Calvet M, Ill\u00e1n-Gala I, Blesa R, Clarim\u00f3n J, et al. CSF sAPP\u03b2, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017;89(2):178\u201388.","journal-title":"Neurology"},{"issue":"17","key":"1696_CR26","doi-asserted-by":"publisher","first-page":"e1619","DOI":"10.1212\/WNL.0000000000006383","volume":"91","author":"I Ill\u00e1n-Gala","year":"2018","unstructured":"Ill\u00e1n-Gala I, Alcolea D, Montal V, Dols-Icardo O, Mu\u00f1oz L, de Luna N, et al. CSF sAPP\u03b2, YKL-40, and NfL along the ALS-FTD spectrum. Neurology. 2018;91(17):e1619\u201328.","journal-title":"Neurology"},{"issue":"7","key":"1696_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.0000000000001859","volume":"85","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Mart\u00ednez-Lage P, S\u00e1nchez-Juan P, Olazar\u00e1n J, Ant\u00fanez C, Izagirre A, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85(7):626\u201333.","journal-title":"Neurology"},{"issue":"1","key":"1696_CR28","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1038\/s41598-021-86349-1","volume":"11","author":"E Mui\u00f1o","year":"2021","unstructured":"Mui\u00f1o E, Maisterra O, Jim\u00e9nez-Balado J, Cullell N, Carrera C, Torres-Aguila NP, et al. Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment. Sci Rep. 2021;11(1):6846.","journal-title":"Sci Rep"},{"issue":"4","key":"1696_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3233\/JAD-131334","volume":"39","author":"D Alcolea","year":"2014","unstructured":"Alcolea D, Mart\u00ednez-Lage P, Izagirre A, Clerigu\u00e9 M, Carmona-Iragui M, Alvarez RM, et al. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: a multicenter study in Spain. J Alzheimers Dis. 2014;39(4):719\u201326.","journal-title":"J Alzheimers Dis"},{"key":"1696_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fnagi.2018.00138","volume":"10","author":"S Lehmann","year":"2018","unstructured":"Lehmann S, Delaby C, Boursier G, Catteau C, Ginestet N, Tiers L, et al. Relevance of A\u03b242\/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Front Aging Neurosci. 2018;10:138.","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1696_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/nl060227d","volume":"6","author":"DM Rissin","year":"2006","unstructured":"Rissin DM, Walt DR. Digital concentration readout of single enzyme molecules using femtoliter arrays and Poisson statistics. Nano Lett. 2006;6(3):520\u20133.","journal-title":"Nano Lett"},{"issue":"7691","key":"1696_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"1","key":"1696_CR33","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1038\/s41467-021-24319-x","volume":"12","author":"A Lle\u00f3","year":"2021","unstructured":"Lle\u00f3 A, Zetterberg H, Pegueroles J, Karikari TK, Carmona-Iragui M, Ashton NJ, et al. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome. Nat Commun. 2021;12(1):4304.","journal-title":"Nat Commun"},{"issue":"11","key":"1696_CR34","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","volume":"92","author":"D Alcolea","year":"2021","unstructured":"Alcolea D, Delaby C, Mu\u00f1oz L, Torres S, Estell\u00e9s T, Zhu N, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92(11):1206\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1696_CR35","doi-asserted-by":"crossref","unstructured":"Delaby C VJ Bros P, Gabelle A, Lefebvre T, Puy H, Hirtz C, Lehmann S. Clinical measurement of Hepcidin-25 in human serum: is quantitative mass spectrometry up to the job? EuPA Open Proteomics. 2014;3:60\u20137.","DOI":"10.1016\/j.euprot.2014.02.004"},{"issue":"1","key":"1696_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JAD-200162","volume":"76","author":"P Chatterjee","year":"2020","unstructured":"Chatterjee P, Mohammadi M, Goozee K, Shah TM, Sohrabi HR, Dias CB, et al. Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-\u03b2 Load. J Alzheimers Dis. 2020;76(1):291\u2013301.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1696_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archpsyc.57.1.47","volume":"57","author":"G Bartzokis","year":"2000","unstructured":"Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry. 2000;57(1):47\u201353.","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"1696_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076203","volume":"8","author":"Z Luo","year":"2013","unstructured":"Luo Z, Zhuang X, Kumar D, Wu X, Yue C, Han C, et al. The correlation of hippocampal T2-mapping with neuropsychology test in patients with Alzheimer\u2019s disease. PLoS ONE. 2013;8(9): e76203.","journal-title":"PLoS ONE"},{"issue":"4","key":"1696_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76(4):509\u201321.","journal-title":"Ann Neurol"},{"issue":"2","key":"1696_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal. 2014;21(2):195\u2013210.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"1696_CR41","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep. 2017;7(1):1398.","journal-title":"Sci Rep"},{"key":"1696_CR42","doi-asserted-by":"publisher","unstructured":"Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, et al. Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2025;82(1):11-18. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3733.","DOI":"10.1001\/jamaneurol.2024.3733"},{"key":"1696_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170169","volume":"122","author":"MG Fleszar","year":"2019","unstructured":"Fleszar MG, Wi\u015bniewski J, Berdowska I, Zieli\u0144ski B, Zboch M, Diakowska D, et al. Systemic hepcidin quantified with LC-MS\/MS in dementia in association with disease pathology and severity and with structural changes in the brain. Peptides. 2019;122: 170169.","journal-title":"Peptides"},{"key":"1696_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","volume":"74","author":"E Nemeth","year":"2023","unstructured":"Nemeth E, Ganz T. Hepcidin and Iron in Health and Disease. Annu Rev Med. 2023;74:261\u201377.","journal-title":"Annu Rev Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01696-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01696-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01696-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:49:11Z","timestamp":1739425751000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01696-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01696-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the patients at each clinical centre gave their written informed consent to participating in clinical research on CSF biomarkers, which\u00a0was approved by the respective Ethics Committees. The committee responsible in Montpellier was the regional Ethics Committee of the Montpellier\u00a0University\u00a0Hospital\u00a0and Montpellier CSF-Neurobank\u00a0#DC-2008\u2013417 at the certified NFS 96\u2013900 CHU resource center BB-0033\u201300031,\u00a0\n                      \n                      . Authorization to handle personal data was granted by the French Data Protection Authority (CNIL) under the number 1709743 v0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"H.Z has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease).D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}